Healthcare Press

Roche Secures Promising Bowel Disease Therapy—Which Could Help Treat Crohn’s—In $7.1 Billion Telavant Deal

  • 📰 ForbesTech
  • ⏱ Reading Time:
  • 23 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 13%
  • Publisher: 59%

Health Health Headlines News

Health Health Latest News,Health Health Headlines

I am a senior reporter for the Forbes breaking news team, covering health and science from the London office. Previously I worked as a reporter for a trade publication covering big data and law and as a freelance journalist and policy analyst covering science, tech and health.

Israel Carries Out Fresh Strikes In Gaza As Biden And Western Leaders Urge Other Middle Eastern Powers To Prevent Escalation

‘Captain Marvel' Sequel Could Bring In Half Of Original Amid ‘Superhero Fatigue’—Here Are The Best And Worst Performing Films Of The Genre It will give Roche the rights to develop, manufacture and commercialize Telavant’s experimental antibody therapy, RVT-3101, in the United States and Japan, which has shown promise as a potential treatment for people suffering from inflammatory bowel diseases like ulcerative colitis and Crohn’s disease.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 318. in HEALTH

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Roche to Buy Bowel-Disease Drug From Roivant, Pfizer for More Than $7 BillionSwiss pharmaceutical giant seeks to bolster pipeline
Source: WSJ - 🏆 98. / 63 Read more »

Swiss pharma giant Roche agrees $7.1 billion deal to buy Telavant HoldingsSwiss health care company Roche announced it would acquire Telavant Holdings Monday, in a deal worth $7.1 billion.
Source: CNBC - 🏆 12. / 72 Read more »